Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H21ClN2O4 |
| Molecular Weight | 388.845 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(OCC(=O)N2CCN(CC3=CC=C4OCOC4=C3)CC2)C=C1
InChI
InChIKey=BFUJHVVEMMWLHC-UHFFFAOYSA-N
InChI=1S/C20H21ClN2O4/c21-16-2-4-17(5-3-16)25-13-20(24)23-9-7-22(8-10-23)12-15-1-6-18-19(11-15)27-14-26-18/h1-6,11H,7-10,12-14H2
| Molecular Formula | C20H21ClN2O4 |
| Molecular Weight | 388.845 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. | 2013-06-17 |
|
| Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. | 2012-10 |
|
| Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. | 2010-05-15 |
|
| Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. | 2010-03-01 |
|
| Metabolomics in drug intolerance. | 2009-11 |
|
| Determining protein adducts of fipexide: mass spectrometry based assay for confirming the involvement of its reactive metabolite in covalent binding. | 2007 |
|
| Investigating the in vitro metabolism of fipexide: characterization of reactive metabolites using liquid chromatography/mass spectrometry. | 2007 |
|
| Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. | 2004-05-25 |
|
| Effects of methyl mercury, mercuric sulfide and cinnabar on active avoidance responses, Na+/K+-ATPase activities and tissue mercury contents in rats. | 2001-04 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3519097
Geriatric patients received 600 mg fipexide daily for a period of 3 weeks. Treatment with fipexide was associated with a significant improvement in each and all monitored symptoms and signs to an average extent of 60%, relative to placebo. Overall, 85% of the patients given fipexide experienced clinical improvement to a greater or lesser degree.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18022964
Rat and human hepatocytes were incubated with 20 and 100 microM fipexide for 0, 2 and 6 hours at 30 deg-C. Samples were then quenched with equal volumes of ice-cold acetonitrile and centrifuged at 12000 rpm for 10 min at 4 deg-C. The supernatant was diluted 1:1 with water prior to injection into LC/MS to test whether the catechol metabolite or fipexide could be profiled for protein binding.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:26:57 GMT 2025
by
admin
on
Mon Mar 31 18:26:57 GMT 2025
|
| Record UNII |
TG44VME01D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN06BX05
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
||
|
WHO-ATC |
N06BX05
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB07630MIG
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
3351
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
m5385
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
TG44VME01D
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
2576
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
34161-24-5
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
758407
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
Fipexide
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
CHEMBL254857
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
251-857-4
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
C038628
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
C65685
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
DB13790
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
1172
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
100000080969
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY | |||
|
DTXSID5044657
Created by
admin on Mon Mar 31 18:26:57 GMT 2025 , Edited by admin on Mon Mar 31 18:26:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |